Story perspectives

NHS Expands Abiraterone Access, Boosts Prostate Cancer Survival

1/20/2026

49 4

Center

NHS England Expands Abiraterone Access

NHS England will provide abiraterone to around 2,000 newly diagnosed men with non-metastatic prostate cancer immediately, with about 7,000 more expected each year.
Abiraterone significantly improves survival, with 86% alive after six years versus 77% on standard treatments.
Prostate Cancer UK is advocating broader prostate-specific antigen (PSA) tests and screening, arguing current guidelines limit proactive discussions for high-risk men and hinder equitable access to early detection.

Left

Prostate Cancer Surge

Prostate cancer became the UK’s most diagnosed cancer in 2022, with 64,425 cases.
Prostate Cancer UK says a 42% rise over the past decade reflects increased awareness campaigns.
The UK National Screening Committee advises against routine screening for most men and its stance has drawn criticism.
Disparities persist, with men in deprived areas more often diagnosed at late stage.

1 of 2

NHS England Expands Abiraterone Access

NHS England will provide abiraterone to around 2,000 newly diagnosed men with non-metastatic prostate cancer immediately, with about 7,000 more expected each year.
Abiraterone significantly improves survival, with 86% alive after six years versus 77% on standard treatments.
Prostate Cancer UK is advocating broader prostate-specific antigen (PSA) tests and screening, arguing current guidelines limit proactive discussions for high-risk men and hinder equitable access to early detection.

1 / 2